glp 1 agonist pcos Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? | Journal of Endocrinological Investigation Therapeutic Potential of Glucagon-like Peptide-1

What is already known on this topic Concerns exist about a potential association between glucagon-like peptide-1 receptor (GLP-1) agonists and suicidality This has prompted regulatory agencies to conduct comprehensive reviews of this drug class Observational studies investigating this safety concern remain inconclusive

There was also an association with pre-operative gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, bloating) and the degree of residual gastric contents

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al

Parlevliet ET, Wang Y, Geerling JJ, et al

GIP, Gastric inhibitory polypeptide